期刊文献+

Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy 被引量:8

PD-1/PD-L1调控及其在肿瘤靶向治疗的前景展望(英文)
下载PDF
导出
摘要 Programmed cell death protein 1(PD-1)/programmed death ligand 1(PD-L1)is a significant immune checkpoint,and the dysfunction of this axis contributes to tumor metastasis and immune escape.PI3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression.Transcriptional factors such as hypoxia induced factors,PTEN,p53,CDK5,BRD4,STAT modulate PD-1/PDL1 expression.PD-1/PD-L1 level is also regulated via epigenetic and post-translational manner.The underlying mechanisms mentioned above may provide potential targets for tumor treatment.At present,the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment. Programmed cell death protein 1(PD-1)/programmed death ligand 1(PD-L1) is a significant immune checkpoint, and the dysfunction of this axis contributes to tumor metastasis and immune escape. PI3 K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression. Transcriptional factors such as hypoxia induced factors, PTEN, p53, CDK5, BRD4, STAT modulate PD-1/PDL1 expression. PD-1/PD-L1 level is also regulated via epigenetic and post-translational manner. The underlying mechanisms mentioned above may provide potential targets for tumor treatment. At present, the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.
出处 《Chinese Medical Sciences Journal》 CAS CSCD 2018年第3期174-182,共9页 中国医学科学杂志(英文版)
关键词 programmed cell DEATH protein 1/programmed DEATH LIGAND 1 IMMUNOTHERAPY REGULATION clinical TRIAL inhibitors programmed cell death protein 1/programmed death ligand 1 immunotherapy regulation clinical trial inhibitors
  • 相关文献

同被引文献37

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部